|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Idec_Pharmaceuticals
|
|
gptkbp:acquisitionYear
|
2003
|
|
gptkbp:CEO
|
gptkb:Christopher_Viehbacher
|
|
gptkbp:collaboratesWith
|
gptkb:Sage_Therapeutics
gptkb:Ionis_Pharmaceuticals
gptkb:Eisai
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focus
|
gptkb:Alzheimer's_disease
multiple sclerosis
neurological diseases
spinal muscular atrophy
|
|
gptkbp:foundedIn
|
1978
|
|
gptkbp:founder
|
gptkb:Phillip_Sharp
gptkb:Heinz_Schaller
gptkb:Walter_Gilbert
gptkb:Charles_Weissmann
gptkb:Kenneth_Murray
gptkb:Francesco_Bellini
gptkb:Luciano_Martini
|
|
gptkbp:hasCompany
|
true
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:logo
|
Biogen logo.svg
|
|
gptkbp:marketCap
|
$40+ billion (2023)
|
|
gptkbp:notableEvent
|
gptkb:Biogen_Conference_COVID-19_outbreak_(2020)
|
|
gptkbp:notableProduct
|
gptkb:Raxibacumab
gptkb:Aducanumab
gptkb:Interferon_beta-1a
gptkb:Natalizumab
|
|
gptkbp:numberOfEmployees
|
~9000
|
|
gptkbp:product
|
gptkb:Aduhelm
gptkb:Avonex
gptkb:Fampyra
gptkb:Plegridy
gptkb:Spinraza
gptkb:Tecfidera
gptkb:Tysabri
|
|
gptkbp:researchArea
|
immunology
neurodegenerative diseases
rare diseases
|
|
gptkbp:revenue
|
$9.8 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Biogen_Idec_Ltd.
|
|
gptkbp:type
|
public
|
|
gptkbp:website
|
https://www.biogen.com
|
|
gptkbp:bfsParent
|
gptkb:^NDX
gptkb:BIIB
|
|
gptkbp:bfsLayer
|
6
|